Who Generates Higher Gross Profit? Vertex Pharmaceuticals Incorporated or Lantheus Holdings, Inc.

Vertex outpaces Lantheus in gross profit growth by 2023.

__timestampLantheus Holdings, Inc.Vertex Pharmaceuticals Incorporated
Wednesday, January 1, 2014125519000519428000
Thursday, January 1, 2015135522000906794000
Friday, January 1, 20161377800001491717000
Sunday, January 1, 20171621350002213533000
Monday, January 1, 20181748850002638058000
Tuesday, January 1, 20191748110003615063000
Wednesday, January 1, 20201387610005469383000
Friday, January 1, 20211876950006670200000
Saturday, January 1, 20225817030007850400000
Sunday, January 1, 20237095430008607000000
Monday, January 1, 20249489600000
Loading chart...

Infusing magic into the data realm

Vertex Pharmaceuticals vs. Lantheus Holdings: A Decade of Gross Profit Growth

In the competitive landscape of the pharmaceutical industry, understanding which companies lead in profitability is crucial. Over the past decade, Vertex Pharmaceuticals Incorporated has consistently outperformed Lantheus Holdings, Inc. in terms of gross profit. From 2014 to 2023, Vertex's gross profit surged by an impressive 1,557%, reaching approximately $8.6 billion in 2023. In contrast, Lantheus Holdings experienced a more modest growth of 465%, culminating in a gross profit of around $709 million in the same year.

Key Insights

  • Vertex's Dominance: By 2023, Vertex's gross profit was nearly 12 times that of Lantheus Holdings.
  • Steady Growth: Both companies showed consistent year-over-year growth, with Vertex maintaining a higher growth trajectory.

This data highlights Vertex's strategic positioning and operational efficiency, making it a formidable player in the pharmaceutical sector.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025